Response to Alam et al., “Association between DPP4 inhibitor use and risk of skin cancer in type 2 diabetes: A real-world cohort study”
Authors:
- 26 March 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , e153-e155
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health (UM1TR004528)
This publication has 3 references indexed in Scilit:
- The role of Dipeptidyl Peptidase‐4 in cutaneous diseaseExperimental Dermatology, 2020
- Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapyNature Immunology, 2015
- Obesity and Risks for Malignant Melanoma and Non-Melanoma Skin Cancer: Results from a Large Danish Prospective Cohort StudyJournal of Investigative Dermatology, 2015